Has Neha Khurana, MD received payments from drug or device companies?

Yes. Drug and device makers reported $68,747 in general payments to Neha Khurana, MD across 203 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Neha Khurana, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Neha Khurana, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Neha Khurana, MD

Psychiatry · Berkeley Lake, GANPI 1659694404

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $54,785 of the $68,747 with a category attached, or 79.7%. Johnson & Johnson accounts for 75.1% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $41,024, more than ten times the $403 reported in 2019. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$68,747in general payments, 2019–2025

Across 203 payments — averaging $338.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$52K
AbbVie$15K
Supernus Pharmaceuticals, Inc.$344
Alkermes, Inc.$318
Teva Pharmaceuticals USA, Inc.$313
Axsome Therapeutics, Inc.$272
plus $1K from 15 others

What the payments were for

Speaking & faculty fees$54,78580%
Travel & lodging$7,85711%
Food & beverage$6,0579%
Education$490%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	105	$51,657
AbbVie	23	$14,584
Supernus Pharmaceuticals, Inc.	12	$344
Alkermes, Inc.	6	$318
Teva Pharmaceuticals USA, Inc.	14	$313
Axsome Therapeutics, Inc.	5	$272
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	10	$229
Takeda Pharmaceuticals U.S.A., Inc.	8	$141
Neurocrine Biosciences, Inc.	1	$138
Corium, LLC	2	$133
E.r. Squibb & Sons, L.L.C.	1	$125
Eisai Inc.	1	$115
Noven Pharmaceuticals, Inc.	1	$114
Bausch Health US, LLC	3	$61
Idorsia Pharmaceuticals US Inc	3	$52
Lundbeck LLC	2	$41
Vanda Pharmaceuticals Inc.	2	$32
Sunovion Pharmaceuticals Inc.	1	$23
Otsuka America Pharmaceutical, Inc.	1	$22
Ironshore Pharmaceuticals Inc.	1	$17
Tris Pharma Inc	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$68,747 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia →

Medicare billing

Part B allowed, 2024

$15,832

Medicare patients

Services billed

145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lisdexamfetamine Dimesylate	13	$3,351
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine	28	$949
Trazodone Hcl	18	$845
Duloxetine Hcl	50	$576
Divalproex Sodium ErDivalproex Sodium	23	$538
Mirtazapine	16	$283
Buspirone Hcl	15	$188
Gabapentin	11	$134
Escitalopram Oxalate	14	$127
Risperidone	17	$97
Sertraline Hcl	16	$33

Paid to pharmacies, not to this prescriber.

Other psychiatry in Berkeley Lake

Richard PettyLoganville$2.9M
Ann GrooverCalhoun$1.4M
Todd AntinDecatur$1M
Michael BanovMarietta$733K
Ben HunterBrookhaven$499K
Joel MorganValdosta$337K
Munjal ShroffSmyrna$316K
David PurselleAtlanta$307K
Jose CangianoAthens$244K
Michael BurkeAtlanta$217K

See the full list for Georgia →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →